MedTrace Logo

A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus

NCT05525234 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-09-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of thalidomide in the treatment of refractory uremic pruritus in maintenance hemodialysis patients.

Conditions

  • Haemodialysis
  • Uremic Pruritus
  • Thalidomide

Interventions

DRUG

Thalidomide

Start with oral thalidomide at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day

DRUG

Placebo

Start with oral placebo at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Renhua Lu, Doctor · Ren Ji Hospital, School of Medicine Shanghai Jiao Tong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-15
Primary Completion
2022-12-31
Completion
2023-01-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05525234 on ClinicalTrials.gov